Darnytsia Continues to Adapt its Medicine Export Strategy to the Realities of War

During the last two years, Darnytsia Pharmaceutical Company managed to restore and surpass the indicators of the export of medicines, which almost completely stopped after the beginning of the full-scale invasion of the russian federation. The share of sales abroad has increased compared to pre-war times to about 4% by the end of 2023, and Australia was added to the list of countries importing Darnytsia products.

“The gradual increase in exports remains one of the key tasks of Darnytsia. This task must be completed for our growth as a company and for the growing popularity of Ukrainian medicines in the world. The successful experience of the countries of Europe, Central Asia, and Australia in terms of purchasing our medicines is already destroying the perception of Ukraine as an exclusively raw and agricultural exporter. We need to strengthen this trend,” Vasyl Hubarets, Head of Corporate Communications at Darnytsia Pharmaceutical Company, says.

Today, the company exports its products to 17 countries of the world, including Iraq, Azerbaijan, Georgia, Uzbekistan, Lithuania, and Poland. Because of the full-scale war, the geography of logistics changed significantly, the transit time of goods increased, but Darnytsia has successfully adapted internal processes and fulfills its obligations to all counterparties.

The year before last, Australia, where Darnytsia underwent a strict compliance procedure, was added to the list of these counterparties. The received confirmation of the stability of the medicine in the southern climatic zone will allow the company to expand cooperation with New Zealand, Malaysia, Yemen, as well as with the countries of North Africa.

At the same time, Darnytsia has long since completely ceased cooperation with counterparties in aggressor states and their accomplices: since 2016, the export of medicines to the russian federation was stopped, and after February 24, 2022, the republic of belarus was also blacklisted. At the same time, all sample packages of medicines that could be supplied to the russian federation and the republic of belarus through third countries were destroyed.

“We focus only on reliable partners, with whom prospects for development and recognition open up for us. It is for these prospects that we have conducted a long and complex preparatory work to obtain GMP (good manufacturing practice) certification and establish research processes in accordance with the standards of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Ukrainian medicines, in particular those produced by Darnytsia, are affordable and of high quality, and are already a worthy competition for the international leaders of the world market,” Vasyl Hubarets adds.